LabGenomics Co Ltd is a Korea-based company principally engaged in the provision of in diagnostic and testing services. The Company provides general diagnostic, sample analysis and various genetic molecular diagnostic such as prenatal malformation testing, cancer genetic testing, chromosome abnormality testing and personal genetic testing. The Company also provides in vitro diagnostic products such as deoxyribonucleic acid (DNA) kits, COVID kits, polymerase chain reaction (PCR) kits and others. In addition, the Company provides biosensor for point of care testing (POCT) and healthy food.

Employees

105

Sector

Healthcare Facilities & Services

Calendar

09-23 - Significant Split/Dividend

More about the company

Quotes

Date	Price	Change	Volume
20/07/26	₩668.00	-7.09%	404,080
16/07/26	₩719.00	+3.16%	370,257
15/07/26	₩697.00	+7.07%	668,471
14/07/26	₩651.00	-5.65%	723,433

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 20/07/2026			5-day change	1st Jan Change
668.00 ^KRW	-7.09%		-11.64%	-63.11%

06-14	Daewoong Bio and LabGenomics Collaborate to Introduce Blood-Based Alzheimer?s Disease Diagnostic Technology in Korea	CI
05-19	LabGenomics Co., Ltd. announced that it has received KRW 20 billion in funding	CI

Market Cap	49.59B 33.62M 29.46M 27.23M 25.04M 47.31M 3.24B 48.05M 326M 128M 1.59B 126M 123M 5.48B	P/E 2024	-7.77x	P/E 2025	-2.09x
Enterprise Value	47.07B 31.92M 27.96M 25.84M 23.77M 44.91M 3.08B 45.61M 309M 121M 1.5B 120M 117M 5.2B	EV / Sales 2024	1.68x	EV / Sales 2025	1.5x
Free-Float	83.31%	Yield 2024 *	-	Yield 2025	-

06-14	Daewoong Bio and LabGenomics Collaborate to Introduce Blood-Based Alzheimer?s Disease Diagnostic Technology in Korea	CI
05-19	LabGenomics Co., Ltd. announced that it has received KRW 20 billion in funding	CI
05-11	LabGenomics Co., Ltd. announced that it expects to receive KRW 20 billion in funding	CI
23/06/25	LabGenomics Appoints CEO	MT
23/07/23	LabGenomics USA LLC announced that it has received KRW 75.948 billion in funding from LabGenomics Co., Ltd.	CI
02/07/23	LabGenomics USA LLC announced that it expects to receive KRW 70 billion in funding from LabGenomics Co., Ltd.	CI
10/04/23	Abion Inc. announced that it expects to receive KRW 21 billion in funding from LabGenomics Co., Ltd., Atinum Investment Co., Ltd, NH Investment & Securities Co., Ltd., Investment and others	CI
09/04/23	N Citron, Inc. announced that it has received KRW 1.999999776 billion in funding from LabGenomics Co., Ltd.	CI
30/03/23	N Citron, Inc. announced that it expects to receive KRW 1.999999776 billion in funding from LabGenomics Co., Ltd.	CI
17/01/23	LabGenomics Co., Ltd. announced that it has received KRW 22.71198072 billion in funding	CI
19/08/22	LabGenomics Co., Ltd. announced that it expects to receive KRW 34.09367874 billion in funding	CI
18/08/22	LabGenomics Co., Ltd. announced that it expects to receive KRW 82.71198072 billion in funding from Luha Private Equity and another investor	CI
27/08/21	LabGenomics Co., Ltd.'s Equity Buyback announced on May 28, 2021, has expired.	CI

1 day	-7.09%
1 week	-11.64%
Current month	-4.30%
1 month	-23.92%
3 months	-62.95%
6 months	-58.92%
Current year	-63.11%

LabGenomics Co., Ltd. Share Price

Stocks

A084650

KR7084650001

Healthcare Facilities & Services

Valuation: LabGenomics Co., Ltd.

Chart: LabGenomics Co., Ltd.

Latest news : LabGenomics Co., Ltd.

Press Releases: LabGenomics Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: LabGenomics Co., Ltd.

Latest insider transactions

Medical & Diagnostic Laboratories

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

Manager	Title	Age	Since
Jae-Hak Ryu CEO	Chief Executive Officer	50	22/06/2025
Mi-Seon Moon AUD	Comptroller/Controller/Auditor	42	30/03/2026

Director	Title	Age	Since
Jong-Hoon Lee BRD	Director/Board Member	42	09/03/2023
Kyung-Deuk Park BRD	Director/Board Member	42	27/03/2024
Yu-Chan Kim BRD	Director/Board Member	59	09/03/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
17/06/24	Jong-Hoon Lee	Buy	Chief Executive Officer	42,000	0.0566%
11/03/24	Gwang-jin Seong	Others		14,104	0.0190%
11/03/24	Gwang-jin Seong	Free		14,104	0.0190%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABGENOMICS CO., LTD.	-7.09%	-11.64%	-71.87%	-85.20%	35.9M
NATERA, INC.	-3.23%	-2.71%	+89.08%	+443.41%	38.87B
LABCORP HOLDINGS INC.	-0.66%	+1.69%	+15.49%	+29.65%	23.24B
SONIC HEALTHCARE LIMITED	-0.91%	+2.07%	-21.48%	-38.60%	7.55B
RADNET, INC.	-2.43%	-7.50%	+5.55%	+76.91%	4.89B
DR. LAL PATHLABS LIMITED	+0.35%	+0.03%	+12.76%	+44.38%	2.93B
NEOGENOMICS, INC.	-2.53%	+0.92%	+128.21%	-20.22%	1.9B
GENEDX HOLDINGS CORP.	-4.46%	-7.60%	-22.11%	+668.69%	1.88B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	+1.21%	+8.41%	-9.74%	-61.82%	1.8B
FLEURY S.A.	+7.53%	+2.54%	+14.13%	+9.23%	1.76B
Average	-1.22%	-0.27%	+14.00%	+106.64%	8.49B
Weighted average by Cap.	-1.85%	+0.85%	+46.33%	+226.98%

	2024	2025
Net sales	85.9B 58.24M 51.02M 47.16M 43.38M 81.95M 5.61B 83.24M 564M 221M 2.75B 219M 214M 9.48B	88.16B 59.77M 52.37M 48.4M 44.52M 84.11M 5.76B 85.43M 579M 227M 2.82B 224M 219M 9.73B
Net income	-23.8B -16.13M -14.13M -13.06M -12.02M -22.7M -1.56B -23.06M -156M -61.2M -761M -60.56M -59.23M -2.63B	-64.37B -43.65M -38.24M -35.34M -32.51M -61.41M -4.21B -62.38M -423M -166M -2.06B -164M -160M -7.11B
Net Debt	-40.66B -27.57M -24.15M -22.32M -20.53M -38.79M -2.66B -39.4M -267M -105M -1.3B -103M -101M -4.49B	-2.52B -1.71M -1.5M -1.38M -1.27M -2.4M -165M -2.44M -16.55M -6.48M -80.54M -6.41M -6.27M -278M

1 week	645	729
1 month	621	948
Current year	621	1,983
1 year	621	2,585
3 years	621	6,500
5 years	621	7,000
10 years	621	9,633.33